FOLLOW US

In a significant expansion of its healthcare empire, Novartis AG announced on Thursday its plans to acquire U.S.-based Mariana Oncology. This deal, valued at up to $1.75 billion, underscores Novartis's commitment to enhancing its precision nuclear medicine offerings.

Novartis to Acquire Mariana for $1.75B : Bolstering the Oncology Portfolio

Novartis will make an initial payment of $1 billion with an additional $750 million earmarked for "potential milestone payments." The specifics of these payments remain undisclosed. The acquisition hinges on several closing conditions, which have not been detailed by Novartis.

Legal Framework and Guidance

Legal expertise for the deal is being provided by Freshfields Bruckhaus Deringer LLP with Jenny Hochenberg and Steven Li leading the team for Novartis. On the other side, Mariana Oncology has enlisted Goodwin Procter LLP, with partners Laura U. Gulick, Kingsley Taft, and associate Sam Beavers at the helm.

Revolutionary Cancer Treatment

Shiva Malek, Novartis's global head of oncology for biomedical research, highlighted the strategic importance of acquiring Mariana's innovative radioligand cancer therapies. Radioligand therapy (RLT) is recognized for its ability to precisely target advanced cancers with minimal collateral damage to surrounding tissues. "We are dedicated to building on our scientific leadership and expanding the breadth of these potentially transformative treatments to a broader range of cancer types," Malek commented.

Mariana Oncology has been proactive in enhancing its manufacturing processes to extend the shelf-life of its radiopharmaceutical products. Its leading therapy, MC-339, targets small cell lung cancer and represents a significant advancement in the treatment options available.

Novartis's Current Radiopharmaceutical Successes

The Novartis radioligand drug portfolio already includes several notable drugs such as Pluvicto, which targets prostate cancer and has recently completed its phase three trial, and Lutathera, aimed at treating a rare cluster of gastrointestinal tumors recently approved by the U.S. Food and Drug Administration.

Novartis to Acquire Mariana for $1.75B : Market Impact

Following the announcement, Novartis shares on the SIX Swiss Exchange saw a closing price of 88.77 Swiss francs ($97.30) on Thursday. The acquisition of Mariana Oncology marks another step in Novartis's strategy to fortify its position in the oncology market, following its recent acquisition of the German biopharmaceutical company MorphoSys AG for €2.7 billion ($2.9 billion).

Novartis to Acquire Mariana for $1.75B : Conclusion

The Novartis to acquire Mariana for $1.75B deal is poised to not only expand Novartis's capabilities in cancer treatment but also to potentially transform the landscape of radiopharmaceutical therapy. As the healthcare industry watches closely, the outcomes of this acquisition could set new standards in the treatment of cancer.